Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sani Kizilbash (NPI 1518172782)

Field	Value
Entity Type	Individual
Organization	Sani Kizilbash
Address	200 1st St Sw
City	Rochester
State	MN
ZIP	55905
Taxonomy	Medical Oncology Physician
NPI Enumerated	May 11, 2007

Payer Source	Total Paid
Medicare	$946.7K
Medicaid	$0

Key Findings

SANI KIZILBASH is an oncology-focused infusional practice: the revenue mix is dominated by high-cost injectable oncology agents, with J9271 (pembrolizumab) generating $456.1K (48.2% of Medicare revenue), J9144 (daratumumab) generating $212.2K (22.4%), and J9299 (nivolumab) generating $119.5K (12.6%). These three immunotherapy/monoclonal antibody drugs together account for 83.3% of the provider's Medicare revenue, which identifies the operation primarily as a drug‑administration infusion service rather than a clinic driven by high-volume E/M billing.

Revenue concentration is extreme in practice: the precomputed top-3 share is 83.3% of total Medicare revenue, meaning a very large portion of billing is tied to a narrow set of biologic agents. That concentration creates clear revenue dependence on reimbursement and utilization of those specific J‑codes rather than on broad-based outpatient visit volume.

This provider is effectively a single‑payer Medicare practice: total Medicare revenue is $946.7K while there is none for Medicaid (no Medicaid billing on file). Analysts should treat this as a Medicare-centric enterprise when assessing payer negotiations, care setting, and financial exposure to changes in Medicare drug reimbursement.

Competitive standing for the top drugs is modest rather than dominant: J9271 ranks #1100 of 1841 nationally (40th percentile; typical, unremarkable volume for this code), J9144 ranks #457 of 615 (26th percentile; typical, unremarkable volume for this code), and J9299 ranks #484 of 505 (4th percentile; typical, unremarkable volume for this code). Those rank/percentile positions indicate the provider is not a national leader for these agents and operates at typical to below‑median volumes versus peers.

Operational mix includes standard chemotherapy administration codes but at low revenue levels relative to the biologics: 96413 appears with $27.7K (2.9% of Medicare revenue) and other administration/add‑on codes such as 96417, 96375, and 96415 each contribute small amounts. This pattern suggests the practice bills for infusion administration and supportive agents but that administration fees are a secondary revenue stream compared with the high-cost drug reimbursements.

Use of biosimilars and supportive agents is present but limited: Q5118 (bevacizumab biosimilar) and Q5119 (rituximab biosimilar) contribute $23.9K (2.5%) and $22K (2.3%), respectively, indicating some uptake of biosimilars alongside brand immunotherapies. These smaller revenue lines may offer operational flexibility but do not materially diversify overall revenue given the top‑3 concentration.

Clinical throughput measured by E/M and infusion initiation codes is relatively low: 99215 yields $4.6K and G0498 yields $7K, both small shares of total Medicare revenue. That combination—high drug revenue with modest E/M and infusion initiation billing—aligns with a service model focused on in‑office drug delivery rather than high volumes of evaluation and management visits.

Tenure supports established practice patterns: the NPI was enumerated 2007-05-11 (~19 years ago), indicating long-standing enrollment in Medicare that likely reflects stable referral relationships and an established infusion workflow. Given the provider's longevity, shifts in market access or Medicare reimbursement for the few top J‑codes would disproportionately affect practice revenues.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

41 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,610	$40	$456.1K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,590	$40	$212.2K
J9299	Injection, nivolumab, 1 mg	4,980	$20	$119.5K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	3,670	$10	$33K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	260	$110	$27.7K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	1,040	$20	$23.9K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	1,000	$20	$22K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	70	$130	$9.4K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	30	$210	$7K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	90	$60	$5K

Showing 1–10 of 41

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 41 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Sani Kizilbash — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

41 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	15	70	7,200	$40	$323.3K
J9144	10	50	3,780	$40	$163.7K
J9299	12	20	5,240	$20	$159.4K
Q5118	7	20	990	$20	$33.7K
Q5119	23	30	1,380	$20	$29.5K
J9264	1	10	2,760	$10	$27.1K
J9217	48	80	80	$130	$17.1K
96413	23	230	70	$100	$11.5K
99214	9,561	10,100	70	$80	$8.1K
99215	1,812	4,060	30	$120	$5.9K

Showing 1–10 of 41

Nearby Providers

Other providers in the same ZIP code as Sani Kizilbash, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$74.3M
Mayo Collaborative Services, Inc	MN	Clinical Medical Laboratory	$6.5M	$39.2M
Mayo Clinic	MN	Clinical Medical Laboratory	$12.2M	$15.2M
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$10.9M
Mayo Foundation For Medical Education & Research	MN	Durable Medical Equipment & Medical Supplies	$9.3K	$2.8M
Vidhu Kaushik	MN	Clinical Pathology/Laboratory Medicine Physician	$59.6K	$1.9M
Roberto Leon Ferre	MN	Medical Oncology Physician	$1.3M	$0
Peter Noseworthy	MN	Cardiovascular Disease Physician	$1.1M	$0
Daniel Childs	MN	Medical Oncology Physician	$1.1M	$0
Robert Jacobson	MN	Pediatrics Physician	$975.6K	$0

Sani Kizilbash — Billing Profile & Reimbursement Data

Sign up for Sani Kizilbash — Billing Profile & Reimbursement Data policy alerts

Sani Kizilbash — Billing Profile & Reimbursement Data

Sign up for Sani Kizilbash — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References